On September 5, 2025 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, reported that the company will participate in the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8–10, 2025, at the Lotte New York Palace Hotel in New York City (Press release, Agenus, SEP 5, 2025, View Source;Wainwright-27th-Annual-Global-Investment-Conference/default.aspx [SID1234655790]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Richard Goldberg, Chief Development Officer, and Dr. Robin Taylor, Chief Commercial Officer, will participate in a fireside chat on Tuesday, September 9, 2025, to provide strategic insights on Agenus’ BOT/BAL immunotherapy program. The discussion will highlight recent pipeline progress, including the launch of the pivotal Phase 3 BATTMAN trial in metastatic colorectal cancer (mCRC), emerging BOT/BAL clinical data across treatment settings, updates on key partnerships, and anticipated milestones for the second half of 2025.
Fireside Chat Details:
Participants:
Dr. Richard Goldberg, Agenus Chief Development Officer
Robin Taylor Ph.D., Agenus Chief Commercial Officer
Date/Time:
Tuesday, September 9, 2025
10:00–10:30 AM EST
Location:
Lotte New York Palace Hotel; NY, NY
Room Kennedy II – 4th Floor
A live webcast of the fireside chat will be available via this link.
A replay of the webcast will be accessible on the investors section of the Agenus website at View Source following the event.